No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
1 mg/kg cnto 136 |
- |
- |
- |
- |
1件: 49 |
2 |
10 mg/kg cnto 136 |
- |
- |
- |
- |
1件: 49 |
3 |
2-deoxy-2 [f-18] fluoro-2-d-glucose |
D-glucose |
D00009 |
- |
- |
1件: 49 |
4 |
4 mg/kg cnto 136 |
- |
- |
- |
- |
1件: 49 |
5 |
81mg aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 49 |
6 |
A-623 |
- |
- |
- |
- |
1件: 49 |
7 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
8 |
Abbv-105 |
- |
- |
- |
- |
2件: 46, 49 |
9 |
Abetimus |
Abetimus |
- |
- |
- |
1件: 49 |
10 |
Abetimus sodium |
Abetimus |
- |
- |
- |
1件: 49 |
11 |
Abetimus sodium (ljp 394) |
Abetimus |
- |
- |
- |
1件: 49 |
12 |
Abr-215757 |
- |
- |
- |
- |
2件: 49, 51 |
13 |
Abt-199 |
- |
- |
- |
- |
1件: 49 |
14 |
Ac0058ta |
- |
- |
- |
- |
1件: 49 |
15 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
16 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
17 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
18 |
Acido micofenolico |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 49 |
19 |
Act-334441 |
- |
- |
- |
- |
1件: 49 |
20 |
Acthar |
Corticotropin |
D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
6件: 2, 13, 46, 49, 50, 222 |
21 |
Acthar gel |
- |
- |
- |
- |
4件: 13, 46, 49, 84 |
22 |
Acthar high dose (80 u) |
- |
- |
- |
- |
1件: 49 |
23 |
Acthar low dose (40 u) |
- |
- |
- |
- |
1件: 49 |
24 |
Ags-009 |
- |
- |
- |
- |
1件: 49 |
25 |
Aidsvax® b/e |
- |
- |
- |
- |
1件: 49 |
26 |
Akbm-3031 |
- |
- |
- |
- |
1件: 49 |
27 |
Aldesleukin |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
3件: 49, 65, 97 |
28 |
Alfacalcidol |
Alfacalcidol |
D01518 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
6件: 41, 46, 49, 50, 96, 235 |
29 |
Alitretinoin |
Alitretinoin |
D02815 |
5件: RARA, RARB, RXRA, RXRB, RXRG |
17件: Acute myeloid leukemia, Adipocytokine signaling pathway, Bile secretion, Estrogen signaling pathway, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
1件: 49 |
30 |
Allogeneic mesenchymal stromal cells derived from the umbilical cord |
- |
- |
- |
- |
1件: 49 |
31 |
Allogeneic msc (allomsc) |
- |
- |
- |
- |
1件: 49 |
32 |
Allogeneic stem cell transplantation |
- |
- |
- |
- |
2件: 49, 84 |
33 |
Alpha-tocopherol |
Tocopherol |
D02332 |
- |
- |
1件: 49 |
34 |
Alx-0061 |
- |
- |
- |
- |
2件: 46, 49 |
35 |
Amg 557 |
- |
- |
- |
- |
1件: 49 |
36 |
Amg 570 |
- |
- |
- |
- |
2件: 46, 49 |
37 |
Amg 592 |
- |
- |
- |
- |
2件: 46, 49 |
38 |
Amg 623 |
- |
- |
- |
- |
1件: 49 |
39 |
Amg 811 |
- |
- |
- |
- |
1件: 49 |
40 |
Amg811 |
- |
- |
- |
- |
1件: 49 |
41 |
Anakinra |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
15件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 84, 86, 106, 107, 299 |
42 |
Anifrolumab |
Anifrolumab |
D11082 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
2件: 46, 49 |
43 |
Anifrolumab 1000 mg |
Anifrolumab |
D11082 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 49 |
44 |
Anifrolumab 300 mg |
Anifrolumab |
D11082 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 49 |
45 |
Anti-cd19-car-t cells |
- |
- |
- |
- |
1件: 49 |
46 |
Anti-cd20 b cell depletion with truxima |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 49 |
47 |
Anti-macrophage migration inhibitory factor (anti-mif) antibody |
- |
- |
- |
- |
1件: 49 |
48 |
Anti-pandemic h1n1 influenza vaccine |
- |
- |
- |
- |
5件: 46, 49, 50, 51, 53 |
49 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
50 |
Asf-1096 cream 0.25% |
- |
- |
- |
- |
1件: 49 |
51 |
Asf-1096 cream 0.5% |
- |
- |
- |
- |
1件: 49 |
52 |
Asf-1096 cream 1.0% |
- |
- |
- |
- |
1件: 49 |
53 |
Aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
54 |
Aspirin and meloxicam |
Meloxicam |
D00969 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
1件: 49 |
55 |
Atacicept |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
56 |
Atacicept 150 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
57 |
Atacicept 75 mg |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 49, 66 |
58 |
Atacicept 75 milligram (mg) |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
59 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
60 |
Autologous ebv specific ctl infusion |
- |
- |
- |
- |
1件: 49 |
61 |
Aviptadil |
Aviptadil |
- |
- |
- |
4件: 49, 51, 85, 86 |
62 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
63 |
Baricitinib |
Baricitinib |
D10308 |
2件: JAK1, JAK2 |
32件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
8件: 41, 46, 49, 50, 93, 107, 265, 325 |
64 |
Belimumab |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
8件: 11, 43, 44, 46, 49, 51, 53, 222 |
65 |
Belimumab 1 mg/kg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 46, 49 |
66 |
Belimumab 10 mg/kg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 43, 46, 49 |
67 |
Belimumab 10 mg/kg plus standard therapy |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
68 |
Belimumab 100 mg sc |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
69 |
Belimumab 10mg/kg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
70 |
Belimumab 200 mg sc |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
71 |
Belimumab 200 mg/ml |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
72 |
Belimumab 4 mg/kg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 46, 49 |
73 |
Belimumab for iv |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
74 |
Belimumab for sc |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
75 |
Belimumab injection |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
76 |
Belimumab or benlysta |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
77 |
Belimumab plus early vaccination |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
78 |
Belimumab plus late vaccination |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
79 |
Benlysta |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
80 |
Benlysta (belimumab) |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 11, 49, 53, 222 |
81 |
Benlysta 400 mg powder for concentrate for solution for infusion |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
82 |
Benlysta™ (belimumab) |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
83 |
Bi 705564 |
- |
- |
- |
- |
1件: 49 |
84 |
Biib059 |
- |
- |
- |
- |
1件: 49 |
85 |
Blisibimod |
Blisibimod |
D10311 |
- |
- |
5件: 43, 44, 49, 63, 66 |
86 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
87 |
Bms-188667 |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
6件: 46, 49, 65, 96, 97, 271 |
88 |
Bms-931699 |
Lulizumab pegol |
- |
- |
- |
2件: 49, 53 |
89 |
Bms-986165 |
- |
- |
- |
- |
3件: 49, 96, 97 |
90 |
Bms-986165 capsule |
- |
- |
- |
- |
1件: 49 |
91 |
Bms-986165 tablet |
- |
- |
- |
- |
1件: 49 |
92 |
Bortezomib |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
13件: 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
93 |
Bos161721 |
- |
- |
- |
- |
1件: 49 |
94 |
Br-dim |
- |
- |
- |
- |
1件: 49 |
95 |
Brentuximab vedotin |
Brentuximab vedotin |
D09587 |
10件: TNFRSF8, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
4件: Cytokine-cytokine receptor interaction, Gap junction, Pathogenic Escherichia coli infection, Phagosome |
2件: 49, 51 |
96 |
Bt063 |
- |
- |
- |
- |
1件: 49 |
97 |
Busulfan |
Busulfan |
D00248 |
- |
- |
13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
98 |
Calcitriol |
Calcitriol |
D00129 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
8件: 37, 46, 49, 66, 96, 158, 235, 326 |
99 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
100 |
Campath |
Alemtuzumab |
D02802 |
- |
- |
4件: 49, 51, 60, 65 |
101 |
Cc-220 |
- |
- |
- |
- |
2件: 49, 84 |
102 |
Cdp3194 |
- |
- |
- |
- |
1件: 49 |
103 |
Cdp7657 |
- |
- |
- |
- |
1件: 49 |
104 |
Cellcept |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
3件: 11, 42, 49 |
105 |
Cenerimod |
Cenerimod |
D11283 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 49 |
106 |
Cenerimod 0.5 mg |
Cenerimod |
D11283 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 49 |
107 |
Cenerimod 1 mg |
Cenerimod |
D11283 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 49 |
108 |
Cenerimod 2 mg |
Cenerimod |
D11283 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 49 |
109 |
Cenerimod 4 mg |
Cenerimod |
D11283 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
1件: 49 |
110 |
Cep-33457 |
- |
- |
- |
- |
1件: 49 |
111 |
Cfz533 |
- |
- |
- |
- |
4件: 11, 46, 49, 53 |
112 |
Chloroquine |
Chloroquine |
D02125, D02366, D03469 |
- |
- |
4件: 46, 49, 95, 130 |
113 |
Cholecalciferol |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 |
114 |
Cholecalciferol and c. xanthorrhiza |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 49 |
115 |
Ciclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
13件: 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
116 |
Ciclosporina |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
2件: 49, 228 |
117 |
Clofarabine |
Clofarabine |
D03546 |
3件: POLA1, POLA2, RRM1 |
6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
118 |
Clopidogrel |
Clopidogrel |
D00769, D07729, D10823, D10824 |
1件: P2RY12 |
1件: Platelet activation |
2件: 49, 86 |
119 |
Conjugated equine estrogens |
Conjugated estrogens |
D04070, D05987 |
- |
- |
1件: 49 |
120 |
Conjugated equine estrogens 0.625 mg/d + mpa 5 mg/d/10d |
Conjugated estrogens |
D04070, D05987 |
- |
- |
1件: 49 |
121 |
Continuation of azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
1件: 49 |
122 |
Corticosteroids |
- |
- |
- |
- |
9件: 41, 46, 49, 64, 97, 164, 220, 296, 300 |
123 |
Corticosteroids (prednisone or prednisolone) |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 49 |
124 |
Creatine |
Creatine |
- |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
125 |
Crestor |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
3件: 49, 79, 299 |
126 |
Csm allogéniques issues de cordons ombilicaux ( mti-pp) |
Afamelanotide |
D10511 |
- |
- |
1件: 49 |
127 |
Ctla4-igg4m (rg2077) |
- |
- |
- |
- |
1件: 49 |
128 |
Ctla4ig |
- |
- |
- |
- |
4件: 46, 49, 96, 271 |
129 |
Cumulative corticosteroid exposure |
- |
- |
- |
- |
1件: 49 |
130 |
Curcumin |
Curcumin |
- |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
131 |
Curcumin supplement |
Curcumin |
- |
- |
- |
1件: 49 |
132 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
133 |
Cyclophosphamide-prednisone-azathioprine |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 49 |
134 |
Cyclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
16件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
135 |
Cyclosporin a |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
11件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 113, 164 |
136 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
137 |
Cyclosporine a |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
8件: 19, 20, 36, 49, 53, 58, 60, 234 |
138 |
Cymbalta |
Duloxetine |
D01179, D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
139 |
Cytarabine |
Cytarabine |
D00168, D03046, D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
140 |
D-glucose |
D-glucose |
D00009 |
- |
- |
3件: 49, 86, 88 |
141 |
Dapagliflozin |
Dapagliflozin |
D08897 |
- |
- |
2件: 49, 222 |
142 |
Dapirolizumab pegol |
- |
- |
- |
- |
1件: 49 |
143 |
Dapirolizumab pegol (dzp) |
- |
- |
- |
- |
1件: 49 |
144 |
Dehydroepiandrosterone |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 49, 53, 83, 96, 113 |
145 |
Dehydroepiandrosterone (dhea) |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 49 |
146 |
Dhea |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
3件: 49, 86, 96 |
147 |
Dihydroartemisinin |
Artenimol |
D07362 |
- |
- |
1件: 49 |
148 |
Dihydroartemisinin tablet |
Artenimol |
D07362 |
- |
- |
1件: 49 |
149 |
Dimethylfumarat |
- |
- |
- |
- |
1件: 49 |
150 |
Diphenhydramine |
Diphenhydramine |
D00300, D00669, D02419, D03285, D03360, D03854 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
5件: 49, 51, 70, 86, 256 |
151 |
Dipyridamole |
Dipyridamole |
D00302 |
2件: PDE4A, PDE5A |
6件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 46, 49, 51, 66, 224 |
152 |
Docosahexaenoic acid |
Doconexent |
- |
- |
- |
7件: 6, 49, 90, 94, 240, 299, 301 |
153 |
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom |
- |
- |
- |
- |
2件: 46, 49 |
154 |
Edratide |
Edratide |
D03957 |
- |
- |
1件: 49 |
155 |
Eicosapentaenoic acid |
Icosapent |
D08061 |
- |
- |
5件: 49, 96, 97, 296, 297 |
156 |
Epa and dha supplementation |
- |
- |
- |
- |
2件: 48, 49 |
157 |
Epratuzumab |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
158 |
Epratuzumab 100 mg |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
159 |
Epratuzumab 1200 mg |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
160 |
Epratuzumab 400 mg |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
161 |
Epratuzumab 600 mg |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
162 |
Epratuzumab iv |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
163 |
Epratuzumab sc |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
164 |
Erl080a |
- |
- |
- |
- |
1件: 49 |
165 |
Estradiol |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
166 |
Ethinyl estradiol |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
3件: 46, 49, 299 |
167 |
Ethylhydrogenfumarat, calciumsalz |
- |
- |
- |
- |
1件: 49 |
168 |
Ethylhydrogenfumarat, magnesiumsalz |
- |
- |
- |
- |
1件: 49 |
169 |
Ethylhydrogenfumarat, zinksalz |
- |
- |
- |
- |
1件: 49 |
170 |
Evobrutinib |
Evobrutinib |
- |
- |
- |
3件: 13, 46, 49 |
171 |
Extended release dipyridamole 200mg/aspirin 25mg |
Dipyridamole |
D00302 |
2件: PDE4A, PDE5A |
6件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 49 |
172 |
Ezetimibe |
Ezetimibe |
D01966 |
1件: NPC1L1 |
1件: Fat digestion and absorption |
4件: 49, 79, 93, 260 |
173 |
Ezetimibe+simvastatin drug combination |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 49 |
174 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
175 |
Fish oil |
Fish oil |
- |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
176 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
177 |
Fludarabine monophosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
4件: 49, 65, 284, 326 |
178 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
11件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
179 |
Fluorine f 18 |
- |
- |
- |
- |
4件: 40, 46, 49, 96 |
180 |
Fluzone |
- |
- |
- |
- |
1件: 49 |
181 |
Focetria (monovalent mf59-adjuvanted vaccine) |
- |
- |
- |
- |
3件: 46, 49, 271 |
182 |
Folate |
Folic acid |
D00070 |
- |
- |
3件: 13, 46, 49 |
183 |
Folatescan (technetium tc 99mec20) |
- |
- |
- |
- |
4件: 13, 46, 49, 96 |
184 |
Folic acid |
Folic acid |
D00070 |
- |
- |
4件: 6, 46, 49, 84 |
185 |
Forigerimod |
Forigerimod |
D09904 |
- |
- |
1件: 49 |
186 |
Fostamatinib |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
4件: 46, 49, 61, 66 |
187 |
Fostamatinib disodium (r935788) |
Fostamatinib |
D09347 |
1件: SYK |
15件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
2件: 46, 49 |
188 |
Fumaderm |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 49 |
189 |
Fumaderm® |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 49 |
190 |
Fumaderm® initial |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
1件: 49 |
191 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
192 |
Gardasil |
Human papillomavirus type 6 l1 capsid protein antigen |
- |
- |
- |
1件: 49 |
193 |
Gc+hcq |
- |
- |
- |
- |
1件: 49 |
194 |
Gdc-0853 |
- |
- |
- |
- |
2件: 46, 49 |
195 |
Gdc-0853 (high dose) |
- |
- |
- |
- |
1件: 49 |
196 |
Gdc-0853 (low dose) |
- |
- |
- |
- |
1件: 49 |
197 |
Gdc-0853 ro7010939 |
- |
- |
- |
- |
2件: 46, 49 |
198 |
Gl701 |
- |
- |
- |
- |
1件: 49 |
199 |
Group a sle prospective study |
- |
- |
- |
- |
1件: 49 |
200 |
Growth colony stimulating factor (g-csf) |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
1件: 49 |
201 |
Gsk1550188 |
- |
- |
- |
- |
3件: 11, 49, 222 |
202 |
Gsk1550188 1mg/kg or 10mg/kg |
- |
- |
- |
- |
1件: 49 |
203 |
Gsk1550188 iv |
- |
- |
- |
- |
1件: 49 |
204 |
Gsk1550188 sc |
- |
- |
- |
- |
1件: 49 |
205 |
Gsk2586184 |
- |
- |
- |
- |
1件: 49 |
206 |
Gsk2586184 100 mg |
- |
- |
- |
- |
1件: 49 |
207 |
Gsk2586184 200 mg |
- |
- |
- |
- |
1件: 49 |
208 |
Gsk2586184 400 mg |
- |
- |
- |
- |
1件: 49 |
209 |
Gsk2586184 50 mg |
- |
- |
- |
- |
1件: 49 |
210 |
Gsk2586184 800mg single and repeat dose |
- |
- |
- |
- |
1件: 49 |
211 |
Gsk2586184 new formulation |
- |
- |
- |
- |
1件: 49 |
212 |
Gsk2586184 standard formulation |
- |
- |
- |
- |
1件: 49 |
213 |
H.p. acthar gel |
- |
- |
- |
- |
5件: 46, 49, 50, 84, 222 |
214 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
215 |
Hgs1006 |
- |
- |
- |
- |
1件: 49 |
216 |
Hgs1006, lymphostat-b, monoclonal anti-blys, lsb, benlysta |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 49, 53 |
217 |
High dietary sodium |
- |
- |
- |
- |
1件: 49 |
218 |
High dose mesenchymal stem cells (mscs) |
- |
- |
- |
- |
1件: 49 |
219 |
Hiomega-3 supplement of naturalis® company - |
- |
- |
- |
- |
1件: 49 |
220 |
Hll2 |
- |
- |
- |
- |
1件: 49 |
221 |
Hll2 (epratuzumab) |
Epratuzumab |
D04036 |
1件: CD22 |
3件: B cell receptor signaling pathway, Cell adhesion molecules (CAMs), Hematopoietic cell lineage |
1件: 49 |
222 |
Hll2 (trivial name or chemical description) |
- |
- |
- |
- |
1件: 49 |
223 |
Hpv prophylactic vaccine gardasil |
- |
- |
- |
- |
1件: 49 |
224 |
Hril-2 active |
- |
- |
- |
- |
3件: 46, 49, 53 |
225 |
Human papillomavirus vaccination (gardasil) |
- |
- |
- |
- |
1件: 49 |
226 |
Human umbilical cord derived msc transplantation for sle |
- |
- |
- |
- |
1件: 49 |
227 |
Hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
228 |
Hydroxychloroquine (z0188) |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 49 |
229 |
Hydroxychloroquine high |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 49 |
230 |
Hydroxychloroquine or chloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 49 |
231 |
Hydroxychloroquine reduced |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 49 |
232 |
Ianalumab |
- |
- |
- |
- |
3件: 35, 49, 53 |
233 |
Ibandronate |
Ibandronate |
D08056 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
2件: 46, 49 |
234 |
Ibandronate+alfacalcidol+calcium |
Alfacalcidol |
D01518 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 49 |
235 |
Ici 182,780 (faslodex) |
- |
- |
- |
- |
1件: 49 |
236 |
Icp-022 |
- |
- |
- |
- |
2件: 46, 49 |
237 |
Ifn-a 2b kinoid drug substance |
- |
- |
- |
- |
1件: 49 |
238 |
Ifn-a2b kinoid |
- |
- |
- |
- |
1件: 49 |
239 |
Ifn-k |
- |
- |
- |
- |
2件: 49, 50 |
240 |
Ifn-kinoid |
- |
- |
- |
- |
2件: 49, 50 |
241 |
Ifn-kinoid drug substance |
- |
- |
- |
- |
2件: 49, 50 |
242 |
Il-2 |
Human interleukin-2 |
- |
- |
- |
5件: 2, 46, 49, 56, 96 |
243 |
Ilt-101 |
- |
- |
- |
- |
1件: 49 |
244 |
Immu-103 |
- |
- |
- |
- |
1件: 49 |
245 |
Immune ablation and hematopoietic stem cell support. |
- |
- |
- |
- |
1件: 49 |
246 |
Immunoglobulin g |
- |
- |
- |
- |
7件: 11, 13, 14, 49, 50, 63, 65 |
247 |
Immunoglobulin g1, anti-(human type i interferon receptor) (human monoclonal medi-546 heavy chain), disulfide with human monoclonal medi-546-chain, dimer |
- |
- |
- |
- |
1件: 49 |
248 |
Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate) |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 49 |
249 |
Individualized dose of rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 49 |
250 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
251 |
Influenz virus surface antigens |
- |
- |
- |
- |
1件: 49 |
252 |
Influenza vaccine (surface antigen, inactivated) |
- |
- |
- |
- |
1件: 49 |
253 |
Influvac |
- |
- |
- |
- |
3件: 46, 49, 50 |
254 |
Interleukin 2 |
Human interleukin-2 |
- |
- |
- |
9件: 46, 49, 51, 56, 63, 95, 96, 97, 271 |
255 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
6件: 2, 35, 49, 55, 65, 97 |
256 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
16件: 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
257 |
Ipp-201101 |
- |
- |
- |
- |
1件: 49 |
258 |
Ipp-201101, p140 |
- |
- |
- |
- |
1件: 49 |
259 |
Iscalimab |
Iscalimab |
D11610 |
1件: CD40 |
16件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Intestinal immune network for IgA production, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Viral myocarditis |
1件: 49 |
260 |
Itolizumab [bmab 600] |
- |
- |
- |
- |
1件: 49 |
261 |
Jbt-101 |
- |
- |
- |
- |
4件: 49, 50, 51, 299 |
262 |
Jnj-55920839 |
- |
- |
- |
- |
1件: 49 |
263 |
Jnj-56022473 |
- |
- |
- |
- |
1件: 49 |
264 |
Kineret |
Anakinra |
D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
5件: 41, 49, 65, 266, 299 |
265 |
Kpg-818 |
- |
- |
- |
- |
1件: 49 |
266 |
Kzr-616 |
- |
- |
- |
- |
3件: 49, 50, 61 |
267 |
L04aa26 |
- |
- |
- |
- |
1件: 49 |
268 |
Laquinimod |
Laquinimod |
- |
- |
- |
4件: 8, 13, 49, 96 |
269 |
Leflunomide |
Leflunomide |
D00749 |
1件: DHODH |
2件: Metabolic pathways, Pyrimidine metabolism |
9件: 11, 40, 46, 49, 53, 66, 224, 271, 300 |
270 |
Lenalidomide |
Lenalidomide |
D04687 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
7件: 16, 26, 28, 34, 49, 284, 300 |
271 |
Levothyroxine |
Levothyroxine |
D01010, D08125 |
2件: THRA, THRB |
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
2件: 49, 78 |
272 |
Ljp 394 |
- |
- |
- |
- |
1件: 49 |
273 |
Ljp394 |
- |
- |
- |
- |
1件: 49 |
274 |
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) |
Estradiol |
D00105, D01413, D01617, D01953, D04061, D04063, D04064, D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
2件: 46, 49 |
275 |
Low dietary sodium |
- |
- |
- |
- |
1件: 49 |
276 |
Low dose mesenchymal stem cells (mscs) |
- |
- |
- |
- |
1件: 49 |
277 |
Low-dose aldesleukin (proleukin®) |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
1件: 49 |
278 |
Lulizumab pegol |
Lulizumab pegol |
- |
- |
- |
1件: 49 |
279 |
Lupuzor |
- |
- |
- |
- |
1件: 49 |
280 |
Ly2127399 |
- |
- |
- |
- |
3件: 13, 46, 49 |
281 |
Ly3009104 |
- |
- |
- |
- |
4件: 46, 49, 50, 325 |
282 |
Ly3361237 |
- |
- |
- |
- |
1件: 49 |
283 |
Lymphostat-b tm |
- |
- |
- |
- |
1件: 49 |
284 |
M2951 |
- |
- |
- |
- |
3件: 13, 46, 49 |
285 |
M2951 (other name: evobrutinib) |
Evobrutinib |
- |
- |
- |
1件: 49 |
286 |
Mabthera (rituximab) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
4件: 13, 46, 49, 53 |
287 |
Medi 545 |
- |
- |
- |
- |
1件: 49 |
288 |
Medi-545 |
- |
- |
- |
- |
2件: 49, 50 |
289 |
Medi-545 600 |
- |
- |
- |
- |
1件: 49 |
290 |
Medi-546 |
- |
- |
- |
- |
1件: 49 |
291 |
Medi-570 0.03 mg |
- |
- |
- |
- |
1件: 49 |
292 |
Medi-570 0.1 mg |
- |
- |
- |
- |
1件: 49 |
293 |
Medi-570 0.3 mg |
- |
- |
- |
- |
1件: 49 |
294 |
Medi-570 1 mg |
- |
- |
- |
- |
1件: 49 |
295 |
Medroxyprogesterone |
- |
- |
- |
- |
1件: 49 |
296 |
Melatonin |
Melatonin |
D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
297 |
Meloxicam |
Meloxicam |
D00969 |
1件: PTGS2 |
20件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
4件: 46, 49, 271, 296 |
298 |
Memantine |
Memantine |
D04905, D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
299 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
300 |
Mesna |
Coenzyme m |
- |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
301 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
302 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
303 |
Methotrexate and folic acid |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 49 |
304 |
Methyl prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 43, 49, 96 |
305 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
306 |
Micofenolico acido |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 49 |
307 |
Milatuzumab |
Milatuzumab |
D08944 |
1件: CD74 |
3件: Antigen processing and presentation, Herpes simplex virus 1 infection, Tuberculosis |
1件: 49 |
308 |
Milnacipran |
Milnacipran |
D08222 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
2件: 46, 49 |
309 |
Mizoribine |
Mizoribine |
D01392 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 49, 51, 53, 66, 94, 222, 224 |
310 |
Modafinil |
Modafinil |
D01832 |
- |
- |
4件: 6, 13, 49, 93 |
311 |
Mofetil |
- |
- |
- |
- |
1件: 49 |
312 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
313 |
Moxifloxacin |
Moxifloxacin |
D00874, D08237 |
- |
- |
8件: 2, 6, 46, 49, 85, 86, 240, 299 |
314 |
Mra 003 us |
- |
- |
- |
- |
1件: 49 |
315 |
Msc treatment |
- |
- |
- |
- |
1件: 49 |
316 |
Msc2364447c |
- |
- |
- |
- |
1件: 49 |
317 |
Mt-1303 high dose |
- |
- |
- |
- |
1件: 49 |
318 |
Mt-1303 low dose |
- |
- |
- |
- |
1件: 49 |
319 |
Mti |
Afamelanotide |
D10511 |
- |
- |
1件: 49 |
320 |
Multivitamin |
Cyanocobalamin |
D00166, D03615, D03616, D03617 |
- |
- |
1件: 49 |
321 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
322 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
323 |
Mycophenolate mofetil (mmf) |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
4件: 49, 60, 66, 222 |
324 |
Mycophenolate motetil |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
1件: 49 |
325 |
Mycophenolic acid |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 11, 49, 51, 60, 66, 96, 222 |
326 |
Myfortic |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
4件: 49, 66, 222, 228 |
327 |
N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide |
- |
- |
- |
- |
1件: 49 |
328 |
N-acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
10件: 6, 13, 19, 20, 49, 58, 85, 111, 164, 299 |
329 |
Nelfinavir |
Nelfinavir |
D00899, D08259 |
- |
- |
3件: 49, 265, 331 |
330 |
Nicotinamide |
Nicotinamide |
D00036 |
- |
- |
3件: 6, 49, 162 |
331 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
332 |
Nktr-358 |
- |
- |
- |
- |
1件: 49 |
333 |
Nnc 0151-0000-0000 |
- |
- |
- |
- |
2件: 46, 49 |
334 |
Nnc0114-0006 |
- |
- |
- |
- |
2件: 46, 49 |
335 |
Norethindrone |
Norethisterone |
D00182, D00953 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
4件: 13, 46, 49, 299 |
336 |
Normal saline |
- |
- |
- |
- |
14件: 6, 17, 22, 36, 46, 49, 60, 94, 96, 211, 226, 276, 296, 299 |
337 |
Nox-e36 |
- |
- |
- |
- |
1件: 49 |
338 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
339 |
Ocrelizumab |
Ocrelizumab |
D05218 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
3件: 13, 46, 49 |
340 |
Olive |
Olea europaea leaf |
- |
- |
- |
3件: 13, 49, 53 |
341 |
Olive oil |
Olive oil |
D03311 |
- |
- |
3件: 13, 49, 53 |
342 |
Omacor |
Omega-3-acid ethyl esters |
D05255 |
2件: CETP, LPL |
4件: Alzheimer disease, Cholesterol metabolism, Glycerolipid metabolism, PPAR signaling pathway |
1件: 49 |
343 |
Omega-3 |
Omega-3 fatty acids |
- |
- |
- |
7件: 13, 46, 49, 66, 79, 96, 299 |
344 |
Oral prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 49, 145 |
345 |
Oral prednisone 5mg |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 49 |
346 |
Ortho-novum 777 |
- |
- |
- |
- |
1件: 49 |
347 |
Oxygen |
Oxygen |
D00003 |
- |
- |
14件: 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 299, 330 |
348 |
Ozone |
Ozone |
- |
- |
- |
2件: 49, 51 |
349 |
Paquinimod |
Paquinimod |
- |
- |
- |
2件: 49, 51 |
350 |
Pf-04236921 |
- |
- |
- |
- |
2件: 49, 96 |
351 |
Pf-06700841 |
- |
- |
- |
- |
3件: 49, 96, 97 |
352 |
Pf-06700841 15 mg |
- |
- |
- |
- |
1件: 49 |
353 |
Pf-06700841 30 mg |
- |
- |
- |
- |
1件: 49 |
354 |
Pf-06700841 45 mg |
- |
- |
- |
- |
1件: 49 |
355 |
Pf-06835375 |
- |
- |
- |
- |
2件: 46, 49 |
356 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
357 |
Phosphate-buffered saline |
Phosphate ion |
- |
- |
- |
1件: 49 |
358 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
359 |
Pitavastatin |
Pitavastatin |
D01862 |
- |
- |
1件: 49 |
360 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
361 |
Plaquenil |
Hydroxychloroquine |
D08050 |
- |
- |
4件: 46, 49, 53, 96 |
362 |
Pneumovax |
- |
- |
- |
- |
3件: 46, 49, 96 |
363 |
Prasterone |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 49 |
364 |
Prasterone (gl701) |
Prasterone |
D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
1件: 49 |
365 |
Pravastatin |
Pravastatin |
D00893, D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
366 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
367 |
Prednisona |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 49, 222 |
368 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
369 |
Prednisone acetate |
Prednisone acetate |
D08416 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 40, 49, 224 |
370 |
Prednisone discontinuation |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 49 |
371 |
Premarin and provera |
- |
- |
- |
- |
1件: 49 |
372 |
Prevenar® and pneumo23® |
- |
- |
- |
- |
1件: 49 |
373 |
Proleukin |
Aldesleukin |
D00748 |
3件: IL2RA, IL2RB, IL2RG |
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
2件: 2, 49 |
374 |
Quinipril |
- |
- |
- |
- |
1件: 49 |
375 |
R-salbutamol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 49 |
376 |
R-salbutamol sulphate |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 49 |
377 |
R932333 |
- |
- |
- |
- |
1件: 49 |
378 |
Rabbit |
Rabbit |
- |
- |
- |
7件: 13, 49, 51, 60, 65, 96, 285 |
379 |
Rabbit anti-thymocyte globulin |
Rabbit |
- |
- |
- |
2件: 49, 65 |
380 |
Rabbit antithymocyte globulin |
Rabbit |
- |
- |
- |
3件: 49, 60, 96 |
381 |
Ramipril |
Ramipril |
D00421 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
7件: 46, 49, 66, 67, 113, 218, 257 |
382 |
Rankl/opg ratio |
- |
- |
- |
- |
1件: 49 |
383 |
Rapamycin |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
16件: 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
384 |
Raptiva |
Efalizumab |
D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
3件: 37, 49, 53 |
385 |
Rayos |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 49 |
386 |
Rc18 160 mg plus standard therapy |
- |
- |
- |
- |
1件: 49 |
387 |
Rc18 240 mg plus standard therapy |
- |
- |
- |
- |
1件: 49 |
388 |
Rc18 80 mg plus standard therapy |
- |
- |
- |
- |
1件: 49 |
389 |
Remicade |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
8件: 46, 49, 56, 84, 85, 96, 97, 271 |
390 |
Rhumab 2h7 |
- |
- |
- |
- |
3件: 13, 46, 49 |
391 |
Rhumab ifnalpha |
- |
- |
- |
- |
1件: 49 |
392 |
Riquent |
- |
- |
- |
- |
1件: 49 |
393 |
Rituxan (rituximab) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 49 |
394 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
395 |
Rivaroxaban |
Rivaroxaban |
D07086 |
1件: F10 |
1件: Complement and coagulation cascades |
2件: 46, 49 |
396 |
Ro 106-1443 |
- |
- |
- |
- |
1件: 49 |
397 |
Ro 496-4913 |
- |
- |
- |
- |
2件: 46, 49 |
398 |
Ro7010939/f13 |
- |
- |
- |
- |
1件: 49 |
399 |
Rontalizumab |
Rontalizumab |
D09662 |
13件: IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 |
22件: Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis |
1件: 49 |
400 |
Rosuvastatin |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
401 |
Rosuvastatin calcium |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
3件: 49, 79, 299 |
402 |
Royal jelly |
Royal jelly |
D09754 |
- |
- |
1件: 49 |
403 |
Rslv-132 |
- |
- |
- |
- |
2件: 49, 53 |
404 |
Salbutamol |
Salbutamol |
D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 3, 11, 49, 85, 86, 228, 256, 299 |
405 |
Same |
Ademetionine |
D07128 |
- |
- |
15件: 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
406 |
Sar113244 |
- |
- |
- |
- |
1件: 49 |
407 |
Sbi-087 |
- |
- |
- |
- |
2件: 46, 49 |
408 |
Sc belimumab 200 mg |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
1件: 49 |
409 |
Sifalimumab |
Sifalimumab |
D09668 |
13件: IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 |
22件: Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis |
1件: 49 |
410 |
Sifalimumab 1,200 mg |
Sifalimumab |
D09668 |
13件: IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 |
22件: Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis |
1件: 49 |
411 |
Sifalimumab 200 mg |
Sifalimumab |
D09668 |
13件: IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 |
22件: Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis |
1件: 49 |
412 |
Sifalimumab 600 mg |
Sifalimumab |
D09668 |
13件: IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 |
22件: Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis |
1件: 49 |
413 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
414 |
Sm101 |
- |
- |
- |
- |
3件: 49, 63, 66 |
415 |
Sm934 |
- |
- |
- |
- |
1件: 49 |
416 |
Sodium-2-mercapto ethane sulphonate |
- |
- |
- |
- |
1件: 49 |
417 |
Soluble fc receptor |
- |
- |
- |
- |
1件: 49 |
418 |
Soluble fc-gamma receptor iib |
- |
- |
- |
- |
1件: 49 |
419 |
Sq fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 49 |
420 |
Standard dose of rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 49 |
421 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
422 |
Standard therapy |
- |
- |
- |
- |
2件: 49, 97 |
423 |
Standard therapy (excluding immunosuppressants) |
- |
- |
- |
- |
1件: 49 |
424 |
Standard therapy (including immunosuppressants) |
- |
- |
- |
- |
1件: 49 |
425 |
Stelara |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
3件: 49, 96, 269 |
426 |
Steriod taper |
- |
- |
- |
- |
1件: 49 |
427 |
Subcuvia |
- |
- |
- |
- |
3件: 14, 49, 65 |
428 |
Sugar pill |
- |
- |
- |
- |
7件: 6, 49, 67, 70, 86, 206, 226 |
429 |
Sulfamethoxazole |
Sulfamethoxazole |
D00447 |
- |
- |
4件: 44, 49, 85, 299 |
430 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
431 |
Switch to myfortic |
- |
- |
- |
- |
1件: 49 |
432 |
Tab08 |
- |
- |
- |
- |
2件: 46, 49 |
433 |
Tabalumab |
Tabalumab |
D10083 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 46, 49 |
434 |
Tabalumab auto-injector |
Tabalumab |
D10083 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 46, 49 |
435 |
Tabalumab prefilled syringe |
Tabalumab |
D10083 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
2件: 46, 49 |
436 |
Taci-fc5 |
Atacicept |
D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
3件: 13, 46, 49 |
437 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
438 |
Tak-079 |
- |
- |
- |
- |
1件: 49 |
439 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
440 |
The generic name is warfarin and many producers will be involved |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
1件: 49 |
441 |
Tocopherol |
Tocopherol |
D02332 |
- |
- |
3件: 13, 49, 257 |
442 |
Tocopherol acetate |
Tocopherol |
D02332 |
- |
- |
1件: 49 |
443 |
Toctino® |
- |
- |
- |
- |
1件: 49 |
444 |
Tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
9件: 46, 49, 50, 51, 84, 96, 97, 107, 271 |
445 |
Tofacitinib citrate |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
3件: 46, 49, 271 |
446 |
Trade name xarelto |
Rivaroxaban |
D07086 |
1件: F10 |
1件: Complement and coagulation cascades |
1件: 49 |
447 |
Trimethoprim |
Trimethoprim |
D00145, D06236 |
- |
- |
6件: 36, 44, 49, 60, 85, 299 |
448 |
Trimethoprim-sulfamethoxazole |
Sulfamethoxazole |
D00447 |
- |
- |
2件: 49, 299 |
449 |
Triptorelin |
Triptorelin |
D06247 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
2件: 49, 76 |
450 |
Triptorelin pamoate |
Triptorelin |
D06247 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
1件: 49 |
451 |
Tru-015 |
- |
- |
- |
- |
3件: 46, 49, 222 |
452 |
Truxima |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 49 |
453 |
Tv-4710 |
- |
- |
- |
- |
1件: 49 |
454 |
Upadacitinib |
Upadacitinib |
D10994 |
1件: JAK1 |
26件: EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
6件: 41, 46, 49, 96, 97, 271 |
455 |
Urine sample |
- |
- |
- |
- |
3件: 49, 51, 61 |
456 |
Ustekinumab |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
457 |
Ustekinumab (approximately 6 mg/kg) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 49 |
458 |
Ustekinumab 90 milligram (mg) |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
1件: 49 |
459 |
Ustekinumab iv |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 49, 97 |
460 |
Ustekinumab sc |
Ustekinumab |
D09214 |
3件: IL12A, IL12B, IL23A |
25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
2件: 49, 97 |
461 |
Vaccination |
- |
- |
- |
- |
1件: 49 |
462 |
Vaccine |
- |
- |
- |
- |
1件: 49 |
463 |
Vay736 |
- |
- |
- |
- |
7件: 13, 35, 46, 49, 53, 85, 95 |
464 |
Velcade® |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
3件: 11, 46, 49 |
465 |
Versus hydroxychloroquine |
Hydroxychloroquine |
D08050 |
- |
- |
1件: 49 |
466 |
Vib7734 |
- |
- |
- |
- |
4件: 49, 50, 51, 53 |
467 |
Vitamin d |
Vitamin d |
- |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
468 |
Vitamin d 25(oh)d |
Vitamin d |
- |
- |
- |
1件: 49 |
469 |
Vitamin d3 |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
11件: 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
470 |
Vitamin d3 400 iu |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 49 |
471 |
Vitamin d3 6000 iu |
Cholecalciferol |
D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
1件: 49 |
472 |
Vitamins: b6, b12, and folate |
Folic acid |
D00070 |
- |
- |
1件: 49 |
473 |
Warfarin |
Warfarin |
D00564, D01280, D08682 |
2件: NQO1, VKORC1 |
5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
10件: 6, 8, 13, 19, 46, 49, 66, 85, 88, 96 |
474 |
Xarelto |
Rivaroxaban |
D07086 |
1件: F10 |
1件: Complement and coagulation cascades |
1件: 49 |
475 |
Xmab5871 |
- |
- |
- |
- |
2件: 49, 300 |
476 |
Zostavax |
- |
- |
- |
- |
1件: 49 |
477 |
Zostavax vaccine |
- |
- |
- |
- |
2件: 46, 49 |